119 related articles for article (PubMed ID: 11395318)
1. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer.
Rao PS; Thakur ML; Pallela V; Patti R; Reddy K; Li H; Sharma S; Pham HL; Diggles L; Minami C; Marcus CS
Nucl Med Biol; 2001 May; 28(4):445-50. PubMed ID: 11395318
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.
Thakur ML; Aruva MR; Gariepy J; Acton P; Rattan S; Prasad S; Wickstrom E; Alavi A
J Nucl Med; 2004 Aug; 45(8):1381-9. PubMed ID: 15299065
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.
Pallela VR; Thakur ML; Chakder S; Rattan S
J Nucl Med; 1999 Feb; 40(2):352-60. PubMed ID: 10025846
[TBL] [Abstract][Full Text] [Related]
4. Imaging tumors in humans with Tc-99m-VIP.
Thakur ML; Marcus CS; Saeed S; Pallela V; Minami C; Diggles L; Pham HL; Ahdoot R; Kalinowski EA; Moody T
Ann N Y Acad Sci; 2000; 921():37-44. PubMed ID: 11193855
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
6. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
[TBL] [Abstract][Full Text] [Related]
7. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
[TBL] [Abstract][Full Text] [Related]
8. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
9. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
10. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro and in vivo properties of [99mTc]cRGD peptides labeled using different novel Tc-cores.
Decristoforo C; Santos I; Pietzsch HJ; Kuenstler JU; Duatti A; Smith CJ; Rey A; Alberto R; Von Guggenberg E; Haubner R
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):33-41. PubMed ID: 17372571
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand.
Wolfe HR; Mendizabal M; Lleong E; Cuthbertson A; Desai V; Pullan S; Fujii DK; Morrison M; Pither R; Waldman SA
J Nucl Med; 2002 Mar; 43(3):392-9. PubMed ID: 11884500
[TBL] [Abstract][Full Text] [Related]
16. [Preparation of (99m)Tc-EDTA-MN and Its Bioimaging in Mouse].
Qi Y; Li G; Chi X; Du L; Huang K; Zhang H; Huang B
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):422-6. PubMed ID: 26182867
[TBL] [Abstract][Full Text] [Related]
17. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.
Maina T; Nikolopoulou A; Stathopoulou E; Galanis AS; Cordopatis P; Nock BA
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1804-14. PubMed ID: 17594090
[TBL] [Abstract][Full Text] [Related]
18. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
19. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
Laverman P; Béhé M; Oyen WJ; Willems PH; Corstens FH; Behr TM; Boerman OC
Bioconjug Chem; 2004; 15(3):561-8. PubMed ID: 15149184
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
